A largely overlooked fact about copper is that at supraphysiological concentrations it doesn't merely impair cells — it hijacks their own metabolic machinery and turns it lethal. Understanding precisely how this happens may open an entirely new therapeutic corridor for cancers and neurodegeneration that are notoriously difficult to target with conventional approaches.
Cuproptosis is a distinct regulated cell death pathway mechanistically separate from the better-known apoptosis and ferroptosis routes. Its defining event is copper binding directly to lipoylated enzymes within the mitochondrial tricarboxylic acid cycle, causing those enzymes to aggregate into insoluble clumps. This aggregation cascade simultaneously depletes iron-sulfur cluster proteins, which are indispensable for electron transport, triggering a wholesale metabolic collapse. The review synthesizes current molecular understanding, maps the crosstalk between cuproptosis and ferroptosis — two metal-driven death programs that share mitochondrial stress as a common node — and frames the pathway's dual relevance: as a vulnerability to exploit in tumors and as a potential contributor to neuronal loss in diseases such as Wilson's disease and Menkes syndrome.
What makes this analysis particularly valuable for the broader longevity and cancer research communities is the conceptual reframe it offers. Most targeted therapies aim to activate apoptosis; cuproptosis provides an orthogonal kill switch that remains functional in apoptosis-resistant malignancies. Copper ionophores like elesclomol, already in clinical trials, operate partly through this mechanism, giving the pathway immediate translational relevance. That said, significant limitations remain: most mechanistic data derive from cell-line models and mouse studies, copper's therapeutic window is narrow and tissue-distribution complex, and the extent to which subclinical copper dysregulation contributes to age-related neurodegeneration in otherwise healthy adults is entirely speculative at this stage. This is confirmatory and synthesizing work — not paradigm-shifting on its own — but it consolidates a rapidly maturing field into a framework that should inform both drug development and dietary copper research.